These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 21785682)
1. From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Dimou A; Harrington K; Syrigos KN Patholog Res Int; 2011; 2011():312346. PubMed ID: 21785682 [TBL] [Abstract][Full Text] [Related]
2. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Toyokawa G; Seto T Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376 [TBL] [Abstract][Full Text] [Related]
4. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). Di Maio M; De Marinis F; Hirsch FR; Gridelli C Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689 [TBL] [Abstract][Full Text] [Related]
6. Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort. Soni S; Rastogi A; Prasad KT; Behera D; Singh N Lung Cancer; 2021 Jan; 151():16-19. PubMed ID: 33278669 [TBL] [Abstract][Full Text] [Related]
7. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099 [TBL] [Abstract][Full Text] [Related]
16. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Zhang YC; Zhou Q; Wu YL Expert Opin Pharmacother; 2016 Aug; 17(12):1693-701. PubMed ID: 27359268 [TBL] [Abstract][Full Text] [Related]
18. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
19. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review). Wang L; Wang W Oncol Rep; 2021 Jan; 45(1):13-28. PubMed ID: 33200229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]